Clinical Trial Update: CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update of CCI-779 (temsirolimus) and bevacizumab in metastatic or unresectable kidney cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• CCI-779 (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-09-11